Você procurou por: kontrollpatienter (Sueco - Inglês)

dk kontrollpatienter.
when combining controlled portions of ten trials (i-ix and charm) and ongoing open label lp

kontrollpatienter erhöll placebo och lågdos prednison eller prednisolon 5 mg två gånger dagligen.
control patients received placebo and low dose prednisone or prednisolone 5 mg twice daily.

hos patienter med måttligt nedsatt njurfunktion reducerades plasmaclearance till 34 % av värdet hos kontrollpatienter.
in patients with moderate renal impairment topotecan plasma clearance was reduced to 34 % of the value in control patients.

det var färre utbrott av aspergillus-infektioner hos patienter som fick posakonazol profylaktiskt jämfört med kontrollpatienter.
there were fewer breakthrough aspergillus infections in patients receiving posaconazole prophylaxis when compared to control patients.

ledipasvirs plasmaexponering (aucinf) var likartad hos patienter med gravt nedsatt leverfunktion och kontrollpatienter med normal leverfunktion.
ledipasvir plasma exposure (aucinf) was similar in patients with severe hepatic impairment and control patients with normal hepatic function.

fler fall av lymfom har observerats bland patienter som får tnf-antagonister i jämförelse med kontrollpatienter, i den kontrollerade delen av kliniska prövningar med tnf-antagonister.
in the controlled portions of clinical trials of tnf-antagonists, more cases of lymphoma have been observed among patients receiving a tnf-antagonist compared with control patients.

i en orienterande klinisk prövning med simponi hos patienter med svår persisterande astma rapporterades fler maligniteter hos patienter som behandlats med simponi jämfört med kontrollpatienter (se avsnitt 4.8).
in an exploratory clinical trial evaluating the use of simponi in patients with severe persistent asthma, more malignancies were reported in patients treated with simponi compared with control patients (see section 4.8).

fler fall av maligniteter, inklusive lymfom har observerats bland patienter som får tnf-antagonister i jämförelse med kontrollpatienter, i den kontrollerade delen av kliniska prövningar med tnf- antagonister.
in the controlled portions of clinical trials of tnf-antagonists, more cases of malignancies including lymphoma have been observed among patients receiving a tnf-antagonist compared with control patients.

frekvensen (95% konfidensintervall) av icke-melanom hudcancer var 8,8 (6,0; 13,0) per 1000 patientår hos humira-behandlade patienter och 3,2 (1,3; 7,6) per 1000 patientår hos kontrollpatienterna.
the rate (95% confidence interval) of non-melanoma skin cancers was 8.8 (6.0, 13.0) per 1,000 patient-years among humira-treated patients and 3.2 (1.3, 7.6) per 1,000 patient-years among control patients.